Charlesworth J A, Quin J W, Macdonald G J, Lennane R J, Boughton C R
Clin Exp Immunol. 1978 Nov;34(2):241-7.
Serial studies of complement, immunoglobulins, lymphocytotoxins and immune complexes were performed in thirteen patients with uncomplicated infectious mononucleosis (IM). Two methods were used to detect immune complexes: a C1q-binding assay (C1q-BA) and the Raji-cell radioimmunoassay (RIA). Patients were followed until there was complete serological recovery. Individual complement components were normal or elevated but three patients showed initial reduction in total haemolytic activity. IgG, IgM, and IgA rose moderately during the acute phase. All sera showed thymocyte-specific cytotoxic activity at some time during the acute phase but were negative by 6 months. The C1q-BA was positive initially in twelve patients but had returned to normal by 6 months. The standard Raji RIA was negative in fifty out of fifty-five samples tested and it is proposed that this reflects the predominant IgM antibody response in these patients. In contrast, incorporation of a multispecific anti-immunoglobulin into this assay yielded data that was frequently positive; these correlated highly with that of the C1q-BA (<0·001). Lymphocytotoxic activity correlated with the C1q-BA (<0·001) and the modified Raji RIA (<0·05). Patterns of lymphocytotoxicity and immune complex reactivity suggested an inverse relationship between these two parameters. It is proposed that this lymphocytotoxicity leads to production of antibody of restricted class permitting enhanced clearance of immune complexes.
对13例无并发症的传染性单核细胞增多症(IM)患者进行了补体、免疫球蛋白、淋巴细胞毒素和免疫复合物的系列研究。采用两种方法检测免疫复合物:C1q结合试验(C1q-BA)和Raji细胞放射免疫测定法(RIA)。对患者进行随访直至血清学完全恢复。单个补体成分正常或升高,但有3例患者最初总溶血活性降低。急性期IgG、IgM和IgA适度升高。所有血清在急性期的某些时间均显示胸腺细胞特异性细胞毒性活性,但6个月时均为阴性。C1q-BA最初在12例患者中呈阳性,但6个月时恢复正常。在检测的55个样本中,50个样本的标准Raji RIA为阴性,推测这反映了这些患者中主要的IgM抗体反应。相比之下,在该检测中加入多特异性抗免疫球蛋白后得到的数据经常为阳性;这些数据与C1q-BA的数据高度相关(<0.001)。淋巴细胞毒性活性与C1q-BA(<0.001)和改良的Raji RIA(<0.05)相关。淋巴细胞毒性和免疫复合物反应模式表明这两个参数之间呈负相关。推测这种淋巴细胞毒性导致产生有限类别的抗体,从而增强免疫复合物的清除。